Biotechnology firm Poseida Therapeutics has signed a worldwide licence agreement with Janssen Biotech to use Centyrin technology to develop chimeric antigen receptor (CAR) therapies.

Under the deal, Poseida will research, develop, manufacture and commercialise licenced products using Janssen Centyrin technology.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Centyrins are a class of Janssen proprietary alternative scaffold molecules, which can be engineered to bind to target proteins with an interface of similar size to those used by antibodies.

"The Centyrin technology can be used to develop binding molecules to numerous cancer antigens and paves the way towards cutting-edge CAR-based immuno-oncology therapeutics."

Poseida Therapeutics CEO Eric Ostertag said: "This licence agreement further strengthens our existing synergistic drug development collaboration and grants Poseida access to a powerful Janssen platform.

"The Centyrin technology can be used to develop binding molecules to numerous cancer antigens and paves the way towards cutting-edge CAR-based immuno-oncology therapeutics, which may eventually treat many different cancers that currently have unsatisfactory treatment options."

See Also:

As part of the agreement, Poseida receives the rights to screen the Centyrin library to identify and develop Centyrin molecules against new cancer antigens that the firm identifies or licences, including solid tumour antigens.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Poseida has licenced the technology to develop pharmaceutical products containing or comprised of autologous T-cells or any NK- or NK-like cells expressing a Centyrin molecule or Centyrin Chimeric Antigen Receptor (CAR) molecule.

The licence allows Poseida to use Centyrin molecules against three existing targets, including one that the firm is developing in house as part of an autologous CAR-T therapy to treat multiple myeloma.

Janssen will receive an undisclosed upfront fee from Poseida, in addition to the potential development, regulatory and commercial milestone payments.